Multiple sclerosis has quietly grown into one of neurology's most consequential chronic burdens.

For decades, major depressive disorder has been managed almost exclusively with SSRIs and SNRIs — drugs that help many patients but leave a large share still symptomatic. That gap is finally narrowing. A wave of mechan

Obesity drug development has moved fast over the last few years, and one of the most closely watched names in the pipeline right now is eloralintide (also known by its research code LY3841136).

Sjögren's disease is a chronic autoimmune condition in which the immune system attacks the glands that produce moisture, most commonly causing dry eyes and dry mouth

Few viral infections carry a public health footprint as wide as HPV. It sits quietly in the epithelial tissue of the skin and mucosa, often without symptoms

The antibody-drug conjugate (ADC) space has grown from a single approval in the early 2000s into one of oncology's most closely watched frontiers.

Rare hemolytic anemias caused by red blood cell enzyme defects have long been underserved in the treatment landscape, but that is beginning to change. Pyruvate kinase disease, more formally known as pyruvate kinase deficiency (PKD)

Drug pricing remains one of the most debated issues in American healthcare. While arguments rage on both sides, one fact is undeniable: a small group of medicines, mostly for rare genetic conditions, carry price tags that put them completely out of reach

The global Intravascular Ultrasound (IVUS) market has emerged as one of the most dynamic segments within interventional cardiology.